Versitech, Inc.

The University of Hong Kong

Sinoclone Ltd

Yi Tsun Richard Kao

Xuechen Li

Ming Liu

Peng Gao

Dan Yang

Kwok Yung Yuen

Jie Zhou

Yu Wang

Kwok-Yung Yuen

Shuofeng Yuan

Chaminda Jayampath Seneviratne

Bojian Zheng

Lakshman Perera Samaranayake

Sze Wah Sarah Wong

Hin Cheung Bill Yam

Ho Ting Iu

Provided herein are compounds, derivatives thereof, and compositions including one or more of the compounds and derivatives, and methods for prevention and/or treatment of microbial infections and/or related diseases or conditions. The present compounds and/or derivatives thereof can be represented by Formula (I): The present methods include administering to a subject an effective amount of one or more compounds of Formula (I). In one embodiment, the microbial infections are bacterial infections. More specifically, the bacterial infections are staphylococcal infections.

Compounds and methods for the treatment of microbial infections

Provided herein are compounds, derivatives thereof, composition comprising one or more of said compounds and derivatives, and methods for prevention and/or treatment of microbial infections and/or related diseases or conditions. The present compounds and/or derivatives thereof can be represented by Formula (II): The present methods include administering to a subject an effective amount of one or more compounds of Formula (II). In one embodiment, said microbial infections are bacterial infections. More specifically, said bacterial infections are staphylococcal infections.

Compounds affecting pigment production and methods for treatment of bacterial diseases

The present invention is a method of inhibiting the replication of an influenza virus by using an antiviral compound to inhibit the binding of an influenza-virus PB2 subunit to an RNA cap. The antiviral compound may be 5-iodo-2-[(3-methyl-4-nitrobenzoyl)amino]benzoic acid; 3,3'-[(4-methylphenyl)methylene]bis(4-hydroxy-2H-chromen-2-one); or 7-(4-hydroxy-2-oxo-2H-chromen-3-yl)-6H,7H,8Hchromeno[3,4&#x2032;:5,6]pyrano[3,2-c]chromene-6,8-dione. The aforementioned antiviral compounds have successfully inhibited the replication of influenza virus in vitro and in vivo in mouse models.

Inhibiting binding of influenza-virus PB2 subunit to RNA cap

Provided herein are compounds, derivatives thereof, composition comprising one or more of said compounds and derivatives, and methods for prevention and/or treatment of microbial infections and/or related diseases or conditions. The present compounds and/or derivatives thereof can be represented by Formula (I): The present methods include administering to a subject an effective amount of one or more compounds of Formula (I). In one embodiment, said microbial infections are bacterial infections. More specifically, said bacterial infections are staphylococcal infections.

Disclosed herein is a novel antifungal compound, derivatives that are used to treat fungal infections. In a specific embodiment, the compound is a small molecule. In a specific embodiment, the compound described herein inhibits yeast to hypha transition under robust hyphal inducing conditions at lower concentration of the molecule. Also disclosed is a composition comprising the antifungal compound. In a specific embodiment, the composition is a pharmaceutical composition. Also disclosed is a method of treating and/or preventing fungal infection using the disclosed compound. The disclosed compound exhibits antifungal activity against wide range of fungal species at slightly higher concentrations. Antifungal compound disclosed herein is used as anti-biofilm agent against fungal infections.

Antifungal compound and uses thereof

Compounds which exhibit antiviral activity, particularly against influenza virus, and methods of making and using thereof are described herein. In one embodiment, the compounds are heterocyclic amides containing piperazine and isozazole rings and optionally substituted with one or more substituents. The compounds can be formulated with one or more pharmaceutically acceptable excipients to form compositions suitable for enteral or parenteral administration. The compounds are preferably used to treat or prevent Influenza A infections, such as H1N1, H2N2, H3N2, H5N1, H7N7, H1N2, H9N2, H7N2, H7N3, and H10N7.

Antiviral compounds and methods of making and using thereof

Growing community of inventors

Hong Kong, China

Yi Tsun Richard Kao